Drugs / ATB-1012
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05573477 | Nov 2022 → Jan 2024 | essential hypertension, type 2 diabetes mellitus | Autotelicbio | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05017987 Comparator | Jun → Jul 2021 | — | Autotelicbio | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATB-1012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05573477 ↗ |
| Known as | ATB-1012 brand name: Forxiga | “ATB-1012 brand name: Forxiga” NCT05017987 ↗ |
| Route | Oral | “Oral tablet” NCT05573477 ↗ |